Sensyne Health announces US launch of GDm-Health
(AIM:SENS ) said it has reached “another major milestone” with its US launch of GDm-Health, its remote monitoring solution for the condition of diabetes in pregnancy which can increase the risk of mothers giving birth as well as the condition of newborns.
Diabetes in pregnancy, a condition which currently affects over 20% of pregnancies in the US can increase the risk of hypertension and caesarean section in mothers as well as preterm birth, birth trauma and admission to neonatal intensive care for newborn babies.
The company told investors that GDm-Health has the potential to ‘significantly improve the way this treatable condition is managed by doctors in collaboration with their patients.’
Sensyne said its first digital healthcare product in the U.S. is being offered to health systems and health plans via the sales force of U.S., Cognizant, its sales and marketing partner.
Virtual care services powered by GDm-Health will qualify for reimbursement under remote patient monitoring codes by the Centers for Medicare and Medicaid Services (CMS) in 2020.
The US launch follows results from a randomised controlled trial conducted in the U.K. which demonstrated a reduction in caesarean sections, improvements in blood glucose monitoring adherence and higher satisfaction with care in women using GDm-Health.
GDm-Health has already demonstrated strong demand in the United Kingdom, achieving a 47% market share across NHS England. To date, the service has been adopted by 50 NHS Trusts across the NHS with a further 7 Trusts in the process of going live, Sensyne noted.
Sensyne is currently concluding a pilot of GDm-Health at Jefferson Health, one of the fastest growing health systems in the U.S. with 14 hospitals with 7,000 nursing staff with 18,000 births a year. Results are expected to be reported in a peer-reviewed journal in early 2021.
The US rollout of GDm-Health will be led and overseen by Derek Baird, the company noted, who was recently appointed as Sensyne's President, North America, and is responsible for driving the commercial development of the Company's North American operations.
“This marks another major milestone in Sensyne's development. The launch of GDm-Health in the U.S. market was a key objective for the Company in this financial year. Entering the U.S. market will help pregnant women and clinicians in the U.S. manage diabetes in pregnancy, improving outcomes for both mothers and babies,” said CEO, Lord Paul Drayson.
“GDM-Health, as a clinically validated solution with proven results, will address one of the key issues: effective management of diabetes in pregnancy,” said Derek Baird, President, North America of Sensyne Health.
He added, “Given the increased reimbursement support for remote patient monitoring and the desire for fewer in-person visits, the timing is right for launch now. We're thrilled to make GDM-Health the first formal U.S. product launch and I look forward to more to come."
Follow News & Updates from here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.